Last edition
News about "Sarclisa "
EU Approves Sanofi's Sarclisa SC as First On-Body Injector Cancer Therapy
Sanofi’s Sarclisa subcutaneous has received EU approval as the first anticancer therapy delivered via an On-Body Injector (OBI). Administered through the CirCLIQ OBI, the treatment offers flexible home or outpatient use for multiple myeloma patients while maintaining efficacy across all approved Sarclisa indications and combinations.
Sarclisa | 09/06/2026 | By News Bureau
US Food and Drug Administration Extends Review Timeline for Sarclisa Subcutaneous Formulation
FDA extends review timeline for Sanofi’s Sarclisa subcutaneous formulation, a potential first-in-class on-body injector therapy for multiple myeloma patients.
Sarclisa | 23/04/2026 | By News Bureau | 150
US FDA Grants Priority Review to Sarclisa for Treatment of Transplant-Ineligible NDMM
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab).
Sarclisa | 28/05/2024 | By Aishwarya | 813
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy